Bausch + Lomb Acquires Eton Pharmaceuticals’ EM-100 Investigational OTC Eye Drop For Allergic Conjunctivitis

Source: Bausch Health Companies

Bausch Health Companies’ subsidiary Bausch + Lomb has acquired the US rights to Eton Pharmaceuticals’ investigational eye drop EM-100. If approved, the eye drop will be the first over-the-counter preservative-free formulation eye drop for the treatment of ocular itching associated with allergic conjunctivitis. EM-100 has been submitted to the FDA for review.

Terms of the deal were not disclosed.

“In 2019, Bausch Health is pivoting to offense by strategically enhancing our pipeline and portfolio. EM-100 is a new, differentiated eye drop that will complement Bausch + Lomb’s broad range of integrated eye health products,” Joseph C. Papa, chairman and CEO, Bausch Health, said in a company news release. “If approved, EM-100 will be the first preservative-free allergy eye drop available in the United States and will allow us to better serve the millions of Americans¬†that experience itchy eyes due to allergies.”

Eton Pharmaceuticals previously reported positive topline results from a phase 3 trial in which EM-100 demonstrated statistically significant superiority to placebo and no adverse events, and demonstrated noninferiority to a comparator product in the treatment of ocular itching.

“We believe that partnering with Bausch + Lomb, a global leader in consumer ophthalmology, will allow us to maximize EM-100’s commercial potential and provide broad accessibility for patients,” Sean Brynjelsen, chief executive officer, Eton Pharmaceuticals, said in the news release.


Related Content